Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- Wall St climbs after August inflation report, oil price slide
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but on track for 8% weekly gain on supply concerns; US diesel hits record high
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Cyclacel Pharma (CYCC) Halted on LUDP
April 4, 2017 10:25 AM EDTCyclacel Pharma (NASDAQ: CYCC) Halted on LUDP
... MoreCyclacel Pharma (CYCC) Continues Monday's Surge Following Preclinical Anti-Cancer Data; Gains Another 40%
April 4, 2017 8:13 AM EDTCyclacel Pharma (NASDAQ: CYCC) adds to Monday's 75% gains after the company announced over the weekend the presentation by independent investigators of preclinical data demonstrating therapeutic potential of CYC065, the Company's second-generation, cyclin-dependent kinase (CDK) 2/9 inhibitor, as a targeted anti-cancer agent.
Shares are up another 40% in pre-open trade to $9.00.
... More
Cyclacel Pharma (CYCC) Surges Following Preclinical Data on CYC065
April 3, 2017 10:09 AM EDTCyclacel Pharma (NASDAQ: CYCC) adds to gains following earlier volatility trading halt and news over the weekend from AACR. Shares are up 54%
Cyclacel Pharma announced the presentation by independent investigators of preclinical data demonstrating therapeutic potential of CYC065, the Company's second-generation, cyclin-dependent kinase (CDK)... More
